Employee benefits plans in Canada, and specifically the prescription drug coverage benefit, are facing new challenges: the growing demand for Ozempic and similar GLP-1 drugs.
Originally developed for Type 2 diabetes, these medications are now at the centre of a booming weight loss movement, raising serious questions for employers, insurers, and plan members alike. Increased demand for GLP-1 drugs is driving costs, complicating coverage, and creating confusion across the benefits landscape. Here’s what you need to know.
Ozempic in Canada: Coverage, Cost, and Benefits Plan Implications
What Is Ozempic and Why Is It So Popular?
Ozempic, also known by its generic name semaglutide, was developed to help manage Type 2 diabetes by regulating blood sugar and stimulating insulin production. However, one of its side effects, significant weight loss, has made it increasingly popular beyond its original medical use.
Fueled by media coverage, celebrity endorsements, and social media trends, Ozempic has entered the public spotlight. It’s part of a broader class of GLP-1 receptor agonists that includes Wegovy, Saxenda, and others.
This cultural moment has driven demand in ways few prescription weight loss drugs have experienced. For benefits plans, this means adjusting to an influx of claims that may not align with the original intent of coverage.
GLP-1 Drugs and Their Growing Demand in Canada
GLP-1 drugs mimic a hormone that helps regulate appetite and glucose. As research continues to support their use for weight loss, Canadian physicians are fielding more requests for these prescriptions, even from individuals without diabetes.
This demand surge has led to supply shortages across provinces. For insurers and plan sponsors, it raises questions around sustainability, clinical appropriateness, and member expectations. The lack of a national policy framework adds further pressure to private plans to define their own approach.
An additional concern is the rising number of patients seeking off-label access, sometimes through less traditional channels. This further muddies the water for plan sponsors trying to manage costs and maintain integrity in benefit offerings.
Are GLP-1s Like Ozempic Covered Under Most Canadian Benefits Plans?
Coverage varies widely. Most employer-sponsored plans cover Ozempic for its approved use, Type 2 diabetes, but many exclude it when prescribed for weight loss.
Even when GLP-1s are listed on a plan’s formulary, access typically requires prior authorization and a formal diagnosis. Physician documentation is often required to confirm that the medication is being used as indicated by Health Canada.
Some plans specifically exclude GLP-1 drugs for weight loss. Others provide limited access through managed formularies or with medical necessity clauses.
This inconsistency in coverage can frustrate members and increase administrative complexity. Clear, well-communicated plan language is key to managing expectations.
The Cost Burden for Plans and Members
GLP-1 drugs are expensive. Ozempic can cost $300–$500 per month, depending on the pharmacy and dosage. For plan sponsors, this raises questions about financial sustainability and plan integrity.
Plan administrators need to weigh:
- Whether long-term access to GLP-1s aligns with their plan’s objectives
- The risk of rising premiums if demand outpaces contributions
- Whether cost-sharing strategies like caps, co-pays, or step therapy are appropriate
Members may also face out-of-pocket expenses if their claims are denied or limited. This creates equity issues, especially if only some employees can afford access outside the plan.
As obesity is increasingly viewed as a chronic health condition, there is growing debate over whether GLP-1s should be classified as essential therapies. In the absence of robust public coverage, the burden is shifting to private plans, whether they’re prepared or not.
Employers should also consider how GLP-1 usage intersects with their broader wellness strategies. When used appropriately and with medical oversight, these medications can contribute to weight management and metabolic health, key factors in long-term health outcomes. However, this benefit must be weighed against plan costs and potential overutilization.
What Employers and Plan Advisors Should Consider
The first step is clarity. Many plans lack specific language around GLP-1 drugs, leading to inconsistencies and confusion.
Employers should partner with experienced benefits consultants to:
- Review drug coverage policies for clarity on GLP-1s
- Define eligibility based on diagnosis, indication, or medical necessity
- Explore cost containment strategies that protect the plan while offering access
There is no one-size-fits-all answer. A tech firm with younger employees may take a different approach than a manufacturing company with older workers or higher diabetes prevalence.
Strategic plan design is critical. It allows employers to align drug coverage with wellness goals, budget realities, and long-term benefit strategies. Proactive education also matters; employees should understand what is covered, why, and how to navigate approvals.
How GLP-1 Coverage Could Shape the Future of Benefits Plans
GLP-1 prescription weight loss drugs are only growing in popularity. New products similar to Ozempic are entering the market and are likely to have the same impact to employee benefits programs in Canada (Saxenda, Wegovy, Rybelsus).
Indications may expand further in the future with public demand only increasing. This is a pivotal moment for group benefits plans in Canada. Employers and plan sponsors who act now can stay ahead of regulatory and market shifts. That means revisiting plan documents, forecasting drug utilization, and engaging expert guidance to build resilient, fair policies.
Benefluent Advisory is a specialized insurance brokerage firm focused on employee benefits and group retirement savings solutions. We work with businesses to design, implement, and administer modern benefit programs that attract and retain talent, improve employee well-being, and align with organizational goals. We are licensed in Ontario, Alberta, and British Columbia, and we maintain international partnerships for organizations with employees in the U.S. and beyond.
Reach out to Benefluent Advisory today at 1 (888) 984-6070 or click here to get in touch online.
